# A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC

> **NCT06598046** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Utidelone and capecitabine

## Key facts

- **NCT ID:** NCT06598046
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-19
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06598046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06598046, "A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06598046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*